Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.

The results of the Prostate Cancer Prevention Trial (PCPT) sparked a debate surrounding the advantages and disadvantages of using the 5-alpha reductase inhibitor finasteride as a chemoprevantative agent against prostate cancer. Over three years after the publication of the PCPT results there is still a reluctance to recommend the use of finasteride in this setting. This Review examines the PCPT data and discusses its results in light of further studies.